MLICM
CMPX icon

Metropolitan Life Insurance Company (MetLife)’s Compass Therapeutics CMPX Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,926
Closed -$3.81K – 455
2024
Q1 		$3.81K Buy
1,926
+804
+72% +$1.39K ﹤0.01% 2264
2023
Q4 		$1.75K Sell
1,122
-4,054
-78% -$7.01K ﹤0.01% 2322
2023
Q3 		$10.2K Hold
5,176
– – ﹤0.01% 2198
2023
Q2 		$16.5K Buy
+5,176
New +$16.3K ﹤0.01% 2033

Other funds holding CMPX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s CMPX Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Compass Therapeutics (CMPX) in Q2 2024, closing a stake of 1,926 shares — an estimated $3.81K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in CMPX in Q2 2023 and held it in 4 quarters. The position peaked at $16.5K in Q2 2023. 82 funds tracked by Wall St. Rank hold CMPX as of Q2 2024.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Compass Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 1,926 Compass Therapeutics shares in Q2 2024, an estimated $3.81K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Compass Therapeutics in Q2 2023 and held it in 4 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Compass Therapeutics position peaked at $16.5K in Q2 2023.
  • 82 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.